The Role of Microbes in Growth and Metastasis of Adenocarcinomas

Dear Colleagues,

We are happy to announce the launch of the Special Issue on microbiome and its impact on pathways involved in the initiation, progression, and therapeutic response related to adenocarcinomas. Adenocarcinoma is a group of cancers involving glandular tissues, including the lung, breast, ovary, pancreas, and prostate. The human microbiome refers to the vast collection of microorganisms that live within and on the human body, including bacteria, viruses, fungi, and other organisms. Microbes sharing typical habitats with humans are known to affect not just physiological aspects but known to impact the course of many diseases. Cancer is no exception, and many research findings have suggested that microbiomes can increase the risk of certain types of cancer. In contrast, the microbiota has been reported to show an anti-tumor response in some cancers.

This Special Issue focuses on how microbiomes can impact the risk of developing adenocarcinoma, cancer initiation and progression, and its impact on the success of therapy, including immunotherapy.

Manuscripts focusing on the following aspects of the microbiome in the context of adenocarcinoma presenting either original research, metanalysis, and reviews are welcome in this Special Issue. Areas to be addressed may include (but are not limited to) the following:

1. Microbiome and risk for developing adenocarcinomas.
2. Microbiome and steroid hormone regulation.
3. The role of the microbiome in adenocarcinoma initiation and pathways involved.
4. Microbiome and tumor progression and metastasis.
5. Microbiome and its impact tumor microenvironment.
6. Microbiome and tumor immunology and immunotherapy.
7. Periodontal disease and risk of adenocarcinomas.

Dr. Rajendra Kumar
Dr. Sheetal Parida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• microbiome
• tumor microenvironment
• tumor immunology
• immunotherapy
• tumor metabolism
• therapy resistance